Can Testicular Cancer Recur After Surgery?

It can. But not often, and not permanently. Stage I disease on active surveillance has a recurrence rate of 15 to 20 percent. Add a single cycle of adjuvant chemo and that drops below 5. Most recurrences happen within the first two years. After five years without a sign? The risk is very small. And here’s the part most patients don’t know going in. Even when testicular cancer comes back, it usually still responds to treatment.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The fear of recurrence after testicular cancer is understandable. But the honest answer? Even if it comes back, it’s usually curable. The tumour markers catch it early, weeks before any scan shows something. The surveillance schedule isn’t just monitoring. It’s the safety net. And it works.”

Stage, type, and what the pathology showed. All three matter.

• Stage I on surveillance: Around 15 to 20 percent of stage I non-seminoma patients on active surveillance relapse. Seminoma runs about the same. Not everyone. But enough that the follow up schedule isn’t optional.
• Adjuvant treatment cuts it sharply: One cycle of BEP for non-seminoma or one to two cycles of carboplatin for seminoma after surgery drops recurrence risk below 5 percent. A small trade-off for a lot of peace of mind.
• Lymph node involvement: Positive retroperitoneal nodes push this into stage II territory. Surveillance alone isn’t standard here. RPLND or chemotherapy gets added.
• Tumour biology details: Lymphovascular invasion, elevated AFP or beta-hCG, high embryonal carcinoma content. These findings in the pathology report push the team toward adjuvant treatment rather than just watching.

For patients whose surveillance or recurrence workup leads to a surgical reassessment of lymph nodes, robotic cancer surgery brings minimally invasive RPLND precision with faster recovery.

Markers first. Scans next. Chemotherapy when needed.

• Tumour markers drawn every visit: AFP and beta-hCG normalise after surgery. A rising number afterwards is the earliest warning. Weeks before anything shows on imaging. That’s why skipping the blood test isn’t an option.
• CT scan schedule: Chest, abdomen, pelvis every 3 to 4 months for the first two years. Then less often. The retroperitoneal lymph nodes are the most common place for relapse to appear first.
• BEP chemotherapy: Three to four cycles of bleomycin, etoposide and cisplatin. Highly effective even for advanced recurrent disease. Cure rates for relapsed testicular cancer sit above 70 percent.
• Second primary risk: The other testicle carries a 2 to 5 percent lifetime risk of a new cancer. Different from recurrence but equally important. Monthly self-examination and any new lump reported promptly.

For a full picture of testicular cancer from diagnosis through to treatment options, our blog on testicular cancer covers the complete picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs radical inguinal orchiectomy and minimally invasive RPLND for testicular cancer, guides post-surgical surveillance and adjuvant therapy decisions through the tumour board, and counsels patients on recurrence risk, follow up schedule and second primary monitoring. Every testicular cancer case is reviewed by the tumour board before the treatment plan is finalised.

That recurrence risk conversation at the first appointment, not as an afterthought weeks later, is what lets patients go into surveillance with a clear plan rather than ongoing anxiety. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.